GLP-1 receptor agonist use in diabetes and obesity has soared, and indications are now expanding into liver diseases, specifically metabolic dysfunction-associated steatohepatitis (MASH). However, the jury is still out on its benefits. AACE President Elect, Scott D. Isaacs, MD, FACP, FACE, provides insights into how the fields of hepatology and endocrinology are tackling the use of GLP-1s for the treatment of patients with MASH and/or obesity and type 2 diabetes, in an article on Healio News.